KRAS G12V mutant peptide–HLA-A*11:01 complex

The KRAS G12V mutant peptide–HLA-A*11:01 complex is a peptide–MHC class I (pHLA) target where a short peptide derived from the oncogenic KRAS p.G12V mutation is bound in the groove of the HLA-A*11:01 heavy chain associated with β2-microglobulin and displayed on the tumor cell surface for CD8 T-cell surveillance. KRAS is a small GTPase oncogene frequently mutated in solid tumors; G12V is among the common hotspot variants and drives constitutive signaling through RAF–MEK–ERK and PI3K pathways. HLA-A molecules present 8–11mer intracellular peptides to T cells; allele A*11:01 predominantly presents 9–10mers and has distinct presentation preferences relevant for vaccine and TCR design. Peptide–HLA structural and database resources catalog many pHLA complexes and guide TCR/vaccine targeting of such neoantigens.

Other names

KRAS G12V–HLA-A*11:01 complexKRAS G12V neoantigen–HLA-A*11:01 complexKRAS G12V peptide–HLA-A11 complexpHLA: KRAS G12V/HLA-A*11:01

TCR recognition of the KRAS G12V peptide bound in the HLA-A*11:01 groove leading to CD8 T-cell activation and cytotoxic killing of presenting tumor cells. Vaccine-induced expansion of KRAS G12V-specific CD8 T cells restricted by HLA-A*11:01.